Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884594 · ClinicalTrials.gov registry record · Phase 1
AAV8-hCocH for Cocaine Use Disorder
A Phase 1 study of Cocaine Dependence, in Remission, sponsored by W. Michael Hooten.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04884594 is a Phase 1 study of Cocaine Dependence, in Remission that is actively recruiting participants, run by W. Michael Hooten. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04884594, a Phase 1 study of Cocaine Dependence, in Remission, is actively recruiting participants, sponsored by W. Michael Hooten.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.
Conditions Studied
Interventions
- DRUG AAV8-hCocH
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04884594
The ClinicalTrials.gov registry entry for NCT04884594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W. Michael Hooten, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine Dependence, in Remission appearing as the primary indexed condition, and to 1 intervention - of which AAV8-hCocH is the first listed.
NCT04884594 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04884594 about?
NCT04884594 is a clinical study titled "AAV8-hCocH for Cocaine Use Disorder". The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission. This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug u...
What is the current status of trial NCT04884594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2021-10-08. Estimated completion is 2026-12.
What conditions does trial NCT04884594 study?
This clinical trial studies the following conditions: Cocaine Dependence, in Remission.
What interventions are being tested in trial NCT04884594?
The interventions under investigation include: AAV8-hCocH (DRUG).
Who is sponsoring clinical trial NCT04884594?
This trial is sponsored by W. Michael Hooten, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04884594 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence, in Remission
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.